Announced details
Complete healing rate at 8 weeks: tegoprazan 84.6% vs. lansoprazole 78.0%; difference: 6.6 percentage points
Complete healing rate at 2 weeks: 76.4% vs. 67.0%; difference: 9.4 percentage points
Two-week healing rate for severe EE: 74.1% vs. 54.5%; difference: 19.6 percentage points
Eight-week healing rate for severe EE: 83.2% vs. 68.0%; difference: 15.2 percentage points
24-week maintenance-of-complete-healing rate across all LA grades: tegoprazan 100 mg, 69.4%; 50 mg, 61.4%; lansoprazole 15 mg, 50.6%
24-week maintenance-of-complete-healing rate for severe EE: tegoprazan 100 mg 76.4% vs. lansoprazole 44.3%; difference: 32.1 percentage points
Cumulative domestic sales in South Korea (outpatient prescription sales): KRW 923.3 billion through 2025. Sold in 20 countries. Business activities, including development, manufacturing and sales, conducted in 57 countries worldwide. Marketing approval obtained in 23 countries worldwide (according to Sebela materials).
In September 2010, the Company entered into an exclusive license agreement for tegoprazan in East Asia with CJ HealthCare Corporation (now HK inno.N Corporation). In November 2019, the partnership was expanded to North America and Europe. In December 2021, HK inno.N Corporation entered into an agreement with Braintree covering the exclusive development, manufacturing and marketing rights in the United States and Canada. The Company is entitled to receive a portion of the revenue that HK inno.N Corporation receives from its partner.
HK Inno.N: headquartered in Osong, South Korea. Sebela: headquartered in Georgia, United States. Sebela focuses on gastrointestinal products and also operates in women's health. Braintree is a division of Sebela that has pursued the research and development, manufacturing and commercialization of gastrointestinal products for more than 40 years. Its locations are in Roswell, Georgia, United States; Braintree, Massachusetts, United States; and Dublin, Ireland.
TRIUMpH-EE：NCT05587309、TRIUMpH-NERD：NCT05587322
HK Inno.N Corporation: Osong, South Korea. Sebela: Georgia, United States. Sebela locations: Roswell, Georgia, United States; Braintree, Massachusetts, United States; and Dublin, Ireland.
The Company will receive no upfront payment in connection with this matter. The Company explained that the matter will contribute to increased value over the medium to long term.
The company does not address Contract Value / Offering price.
Digestive Disease Week® 2026
Sebela Pharmaceuticals press release dated 5 May 2026
American Association for the Study of Liver Diseases（AASLD）
American Gastroenterological Association（AGA）
American Society for Gastrointestinal Endoscopy（ASGE）
Society for Surgery of the Alimentary Tract（SSAT）
| Item | Details |
|---|---|
| Names of Products / Services Covered | tegoprazan, K-CAB® |
| Counterparty | HK inno.N Corporation (HK inno.N), Sebela Pharmaceuticals Inc. (Sebela), Braintree Laboratories, Inc. |
| Counterparty overview | HK Inno.N: headquartered in Osong, South Korea. Sebela: headquartered in Georgia, United States. Sebela focuses on gastrointestinal products and also operates in women's health. Braintree is a division of Sebela that has pursued the research and development, manufacturing and commercialization of gastrointestinal products for more than 40 years. Its locations are in Roswell, Georgia, United States; Braintree, Massachusetts, United States; and Dublin, Ireland. |
| Relationship with the Company | In September 2010, the Company entered into an exclusive license agreement for tegoprazan in East Asia with CJ HealthCare Corporation (now HK inno.N Corporation). In November 2019, the partnership was expanded to North America and Europe. In December 2021, HK inno.N Corporation entered into an agreement with Braintree covering the exclusive development, manufacturing and marketing rights in the United States and Canada. The Company is entitled to receive a portion of the revenue that HK inno.N Corporation receives from its partner. |
| Contract Date | September 2010, November 2019, December 2021 |
| Launch date | Launched in South Korea in 2019 (actual). US approval expected in January 2027. |
| Applicable area | Healing of erosive gastroesophageal reflux disease (EE), Maintenance of healing following healing of EE, Relief of heartburn associated with non-erosive gastroesophageal reflux disease (NERD), Treatment of GERD in adults |
| Registration number and expiry date | TRIUMpH-EE：NCT05587309、TRIUMpH-NERD：NCT05587322 |
| Location | HK Inno.N Corporation: Osong, South Korea. Sebela: Georgia, United States. Sebela locations: Roswell, Georgia, United States; Braintree, Massachusetts, United States; and Dublin, Ireland. |
| Quantitative Effects | Complete healing rate at 8 weeks: tegoprazan 84.6% vs. lansoprazole 78.0%; difference: 6.6 percentage points, Complete healing rate at 2 weeks: 76.4% vs. 67.0%; difference: 9.4 percentage points, Two-week healing rate for severe EE: 74.1% vs. 54.5%; difference: 19.6 percentage points, Eight-week healing rate for severe EE: 83.2% vs. 68.0%; difference: 15.2 percentage points, 24-week maintenance-of-complete-healing rate across all LA grades: tegoprazan 100 mg, 69.4%; 50 mg, 61.4%; lansoprazole 15 mg, 50.6%, 24-week maintenance-of-complete-healing rate for severe EE: tegoprazan 100 mg 76.4% vs. lansoprazole 44.3%; difference: 32.1 percentage points |
| Usage history | Cumulative domestic sales in South Korea (outpatient prescription sales): KRW 923.3 billion through 2025. Sold in 20 countries. Business activities, including development, manufacturing and sales, conducted in 57 countries worldwide. Marketing approval obtained in 23 countries worldwide (according to Sebela materials). |
| Impact on Business Performance | The Company will receive no upfront payment in connection with this matter. The Company explained that the matter will contribute to increased value over the medium to long term. |
| Source | Digestive Disease Week® 2026, Sebela Pharmaceuticals press release dated 5 May 2026, American Association for the Study of Liver Diseases（AASLD）, American Gastroenterological Association（AGA）, American Society for Gastrointestinal Endoscopy（ASGE）, Society for Surgery of the Alimentary Tract（SSAT） |
Items this document does not state (5)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Because Phase 3 trial data were presented orally at DDW 2026. The Company explained that this represents important progress in the development of tegoprazan's business in the United States and will contribute to increased value over the medium to long term.